(1S,2R,3S,5S,16E,18E,20R)-11-chloro-12,20-dimethoxy-2,5,9,16-tetramethyl-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaene-8,23-dione

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: (1S,2R,3S,5S,16E,18E,20R)-11-chloro-12,20-dimethoxy-2,5,9,16-tetramethyl-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaene-8,23-dione
• 化学式: C₂₈H₃₇ClN₂O₆
• 分子量: 533.1
• InChiKey: WMSNBRWBYMHUKB-SKDWMFNYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  37
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  89.6
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] ANTI-CCR7 ANTIBODY DRUG CONJUGATES<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-CCR7
  申请人：NOVARTIS AG

  公开号：WO2018142322A1

  公开（公告）日：2018-08-09

  This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

  本申请公开了抗CCR7抗体、其抗原结合片段，以及所述抗体或抗原结合片段的抗体药物结合物。该发明还涉及使用这些抗体、抗原结合片段和抗体药物结合物治疗或预防癌症的方法。本文还公开了制备这些抗体、抗原结合片段和抗体药物结合物的方法，以及将这些抗体和抗原结合片段用作诊断试剂的方法。
• MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE
  申请人：Regeneron Pharmaceuticals, Inc.

  公开号：US20170209591A1

  公开（公告）日：2017-07-27

  Provided herein are maytansinoid compounds, derivatives thereof, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.

  本文提供了马替西酚类化合物、其衍生物、共轭物以及使用它们治疗或预防增生性疾病的方法。
• Anti-CD123 antibodies and conjugates and derivatives thereof
  申请人：IMMUNOGEN, INC.

  公开号：US10875925B2

  公开（公告）日：2020-12-29

  The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the α chain of the interleukine 3 receptor, or IL-3Rα). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.

  本发明一般涉及与 CD123 抗原（白细胞介素 3 受体或 IL-3Rα 的 α 链）结合的抗体、其抗原结合片段、多肽和免疫结合剂。本发明还涉及使用此类 CD123 结合分子诊断和治疗疾病（如 B 细胞恶性肿瘤）的方法。
• Maytansinoid derivatives, conjugates thereof, and methods of use
  申请人：Regeneron Pharmaceuticals, Inc.

  公开号：US11446389B2

  公开（公告）日：2022-09-20

  Provided herein are maytansinoid compounds, derivatives thereof, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.

  本文提供的是 maytansinoid 化合物、其衍生物、其共轭物，以及用它们治疗或预防增殖性疾病的方法。
• ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF
  申请人：ImmunoGen, Inc.

  公开号：EP3313884B1

  公开（公告）日：2020-11-18